ClinicalTrials.gg
Not yet recruitingNCT07156331REBUILDUpdated Sep 5, 2025

Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes

An observational study in Type 2 Diabetes, sponsored by Kristin Clemens. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Kristin Clemens · Observational

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

One downside of diabetes weight loss drugs like GLP-1RA and GLP-1RA/GIP, is that they can cause muscle loss, which is especially risky for older adults or those already prone to frailty and falls. There is also concern that GLP-1RA might affect bone health, possibly leading to weaker bones and increased risk of fractures. To prevent these issues, doctors need to better predict who is most at risk of muscle and/or bone loss. That way, doctors can adjust patient management-like adding targeted physical therapy, or bone-protecting medications alongside GLP-1RA or GLP-1RA/GIP medications.

Medical imaging can help spot early muscle and bone changes. Advanced imaging, like PET and CT scans allow for the assessment of muscle fat content and blood flow in the bones and muscles. This could provide clearer insights into how GLP-1RA or GLP-1RA/GIP medications affect muscles and bones in ways that matter for patients (strength, mobility, falls risk, etc.).

The investigators will conduct an exploratory study of 20 patients initiating on GLP-1RA or GLP-1RA/GIP by their care provider, and assess their muscle and bone health at baseline, 3, 6, and 12 months using advanced PET/CT imaging. The investigators will also assess functional measures, including grip strength, Timed Up and Go test, and gait speed. The goal is to measure and describe early changes in body composition and physical function that could signal harm. These findings will help to develop a clinical prediction tool for clinicians to use prior to starting semaglutide or tirzepatide, as well as design interventions to help promote healthy muscle and bone while on treatment.

Read the detailed description

In Canada, older adults are projected to represent nearly one-fourth of the population by 2040, with the number of old older adults (75 and older) growing at an even faster rate. This demographic shift has important implications, including a rising prevalence of aging-related disease. Approximately 1 in 4 Canadians aged 65 or older have type 2 diabetes (DM2).

Aging and DM2 often coexists with obesity, chronic kidney disease (CKD) and/or cardiovascular disease (CVD) as well as cardiovascular-kidney-metabolic (CKM) syndrome. Aging and chronic disease also independently elevate the risk of sarcopenia (age-related progressive loss of muscle mass and strength) and frailty.

Glucagon-like peptide 1 receptor agonists (GLP-1RA like Ozempic) have revolutionized the management of chronic metabolic disease. These agents lower blood glucose, promote weight loss, and protect the heart, brain, and kidneys, making them the cornerstone of therapy for diabetes, kidney, cardiovascular, and CKM syndrome. However, concerns have been raised about the amount of weight loss elicited by these medications, particularly the associated loss of skeletal muscle mass. In some studies, weight loss of greater than 10 kg have been described with GLP-1RA (i.e., semaglutide) or GLP-1RA/GIP (tirzepatide) drugs, with up to 40% of total weight loss from lean body mass reported with semaglutide. Loss of lean body mass (including skeletal muscle mass), could be particularly worrisome to those at high risk for frailty and sarcopenia, both of which are associated with increased morbidity, hospitalizations, reduced quality of life, disability and mortality. There is also evidence that these medications could negatively impact bone quality and fracture risk.

Existing studies on the impact of GLP-1RA and GLP-1RA/GIP on lean body mass have been limited; they primarily measured body composition using dual energy x ray absorptiometry (DXA) which is unable to quantify intramuscular fat, and is less sensitive to body thickness and hydration/pathologic status. DXA also has lower precision/accuracy compared with CT scan and MRI, leading to more variability. Among studies that have used MRI to examine body composition, many were secondary analyses of clinical trials, excluded individuals with body mass index (BMI) ≤25 kg/m2 and/or DM2, had short follow-up, and lacked functional assessments. Evidence indicates that intramuscular fat is more strongly associated with adverse outcomes than muscle quantity, highlighting the importance of exploring the impact of GLP-1RA and GLP-1RA/GIP on both muscle mass and muscle composition. There also remains an opportunity to examine the association between changes in body composition and measures of muscle strength/function, which are highly prognostic of outcomes such as disability, hospitalizations, and mortality. There is also a dearth of evidence regarding the impact of GLP-1RA and GLP-1RA/GIP medications on muscle blood flow, glucose metabolism, or bone blood flow, which may correlate with clinically important patient outcomes like falls and fracture.

The investigators propose a single-arm, open-label, prospective study to explore changes in body composition, muscle mass, composition, and function, in patients with DM2 with and without CKM following initiation of a GLP-1RA (semaglutide or Ozempic is the most commonly prescribed) or GLP-1RA/GIP (tirzepatide or Mounjaro is the most commonly prescribed). The goal is to characterize and quantify early changes in muscle and physical function that could signal harm; This will allow the development clinical prediction tool to guide treatment decisions before initiating semaglutide or tirzepatide, and to design targeted interventions aimed at preserving muscle and bone health in real-world patients with type 2 diabetes prescribed GLP-1RA or GLP-1RA/GIP therapies.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • T2DM
  • Type 2 Diabetes
  • Semaglutide
  • Tirzepatide
  • GLP-1RA
  • GLP-1RA/GIP
  • Body Mass
  • Muscle Composition
  • Muscle Mass
  • Mounjaro
  • Ozempic
  • Wegovy
  • DM2
  • Diabetes Mellitus 2
  • Muscle Strength
  • Muscle Function
  • Muscle Preservation
  • Bone Health
03

In context

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 20 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Kristin Clemens is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 or older with type 2 diabetes that have recently been started on semaglutide or tirzepatide under the care of a physician.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years old
  • Have type 2 diabetes
  • Have recently been started on semaglutide or tirzapatide under the care of a physician
  • Be able to speak and read English

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or breastfeeding
  • Are unable to perform functional tests
  • Are unable to provide
  • Have any to PET/CT scan
  • Had a change in body weight over 5 kilograms within 90 days before starting a GLP-1RA or GLP-1RA/GIP
  • Had previous or planned (during the study period) bariatric surgery in the subsequent 12 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults with T2DM that have recently been started on GLP-1RA or GLP-1RA/GIP Medication

    Adults at least 18 years of age that have Type 2 Diabetes, have recently been started on semaglutide or tirzepatide under the care of a physician

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in skeletal muscle mass at 1-year

    Changes in skeletal muscle mass 1-year after initiation semaglutide or tirzepatide. Measured at the L3 lumbar vertebrae with PET-CT, in cm²/m².

    Time frame: Change from baseline to 12 months

  2. Change in Timed Up-and-Go (TUG) at 1-year

    Change in muscle strength and function 1-year after starting semaglutide or tirzepatide. Measures the time in seconds to stand from a standard chair, walk 3 meters, turn, walk back and sit down. Measured in seconds.

    Time frame: Change from baseline to 12 months

  3. Change in Gait Speed at 1-year

    Change in muscle strength and function 1-year after starting semaglutide or tirzepatide. Usual-pace walking speed measured across a 4-meter course with a static start. Measured in meters per second.

    Time frame: Change from baseline to 12 months

  4. Change in Handgrip Strength at 1-year

    Change in muscle strength - handgrip strength change 1-year after starting semaglutide or tizepatide. Measured using handheld dynamometer in the dominant hand, in kg.

    Time frame: Change from baseline to 12 months

Secondary outcomes

  1. Change in skeletal muscle quality at 3 and 6 months

    Changes L3 skeletal muscle radiodensity 3 months and 6 months after initiation of semaglutide or tirzepatide. Measured at L3 lumbar vertebrae with PET-CT, in Hounsfield Units (HU).

    Time frame: Change from baseline to 3 months, change from baseline to 6 months

  2. Change in skeletal muscle quality at 3 and 6 months

    Changes L3 skeletal muscle radiodensity at 3 months and 6 months after initiation of semaglutide or tirzepatide. Measured at L3 lumbar vertebrae with PET-CT, in Hounsfield Units (HU).

    Time frame: Change from baseline to 3 months, change from baseline to 6 months

  3. Change in Timed Up-and-Go (TUG) at 3 and 6 months

    Change in muscle strength and function 3 months and 6 months after starting semaglutide or tirzepatide. Measures the time in seconds to stand from a standard chair, walk 3 meters, turn, walk back and sit down. Measured in seconds.

    Time frame: Change from baseline to 3 months, change from baseline to 6 months

  4. Change in Gait Speed at 3 and 6 months

    Change in muscle strength and function 3 months and 6 months after starting semaglutide or tirzepatide. Usual-pace walking speed measured across a 4-meter course with a static start. Measured in meters per second.

    Time frame: Change from baseline to 3 months, change from baseline to 6 months

  5. Change in Handgrip Strength at 3 and 6 months

    Change in muscle strength - handgrip strength change 3 months and 6 months after starting semaglutide or tizepatide. Measured using handheld dynamometer in the dominant hand, in kg.

    Time frame: Change from baseline to 3 months, change from baseline to 6 months

Other outcomes

  1. Blood Flow in Muscle, Bone and Kidney

    Changes in blood flow in muscle, bone and kidney 1 year after starting semaglutide or tirzepatide.

    Time frame: 12 months

  2. Glucose Metabolism in Muscle, Bone and Kidney

    Changes in glucose metabolism in muscle, bone and kidney 1 year after initiating semaglutide or tirzepatide.

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2027, 24 months later.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 24 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Sep 5, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07156331
Lead sponsor
Kristin Clemens
Responsible party
Kristin Clemens (Associate Professor, Western University, Canada) — Sponsor-investigator
First posted
Sep 5, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 5, 2025

Study contacts

Heather LaPier, BSc
Contact
heather.lapier@sjhc.london.on.ca
519-646-6100 ext. 65373
Kristin Clemens, MD, MSc
principal investigator · St. Joseph's Health Care London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion